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Abstract
An effective way to reduce LDL cholesterol, the primary risk factor of atherosclerotic cardiovascular disease, is to increase
cholesterol excretion from the body. Our group and others have recently found that cholesterol excretion can be facilitated
by both hepatobiliary and transintestinal pathways. However, the lipoprotein that moves cholesterol through the plasma to
the small intestine for transintestinal cholesterol efflux (TICE) is unknown. To test the hypothesis that hepatic very low-
density lipoproteins (VLDL) support TICE, antisense oligonucleotides (ASO) were used to knockdown hepatic expression of
microsomal triglyceride transfer protein (MTP), which is necessary for VLDL assembly. While maintained on a high
cholesterol diet, Niemann-Pick C1-like 1 hepatic transgenic (L1Tg) mice, which predominantly excrete cholesterol via TICE,
and wild type (WT) littermates were treated with control ASO or MTP ASO. In both WT and L1Tg mice, MTP ASO decreased
VLDL triglyceride (TG) and cholesterol secretion. Regardless of treatment, L1Tg mice had reduced biliary cholesterol
compared to WT mice. However, only L1Tg mice treated with MTP ASO had reduced fecal cholesterol excretion. Based upon
these findings, we conclude that VLDL or a byproduct such as LDL can move cholesterol from the liver to the small intestine
for TICE.
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Introduction
Atherosclerotic coronary vascular disease (ASCVD) remains the
number one killer of Americans [1]. There is a strong positive
relationship between low-density lipoprotein cholesterol concen-
tration (LDLc) and ASCVD risk. One way to reduce LDLc, the
primary risk factor of ASCVD, is to increase cholesterol excretion
from the body [2]. Biliary cholesterol secretion is the primary
mechanism by which excess cholesterol is moved into the lumen of
the small intestine and subsequently excreted from the body [3].
However, our group and others have found that cholesterol
excretion can also be facilitated by a non-biliary pathway known
as transintestinal cholesterol efflux (TICE) [4,5]. TICE appears to
involve the movement of cholesterol through the plasma to the
basolateral surface of the enterocytes. The cholesterol is then
internalized, trafficked across the cell, and secreted into the lumen
of the small intestine [4]. Under normal conditions in mice, TICE
has been reported to contribute 20–50% of the cholesterol found
in feces [6–8]. TICE has also been observed in humans but its
quantitative contribution to fecal cholesterol excretion has not
been established [9]. Activation of the nuclear hormone receptors
liver X receptor (LXR) and peroxisome proliferator-activated
receptor delta (PPARd) with agonists has been shown to stimulate
TICE in mice by ,100% [6,10]. In addition, when biliary
cholesterol secretion is absent or dramatically reduced in mice and
humans, normal cholesterol excretion can be maintained by TICE
[7,11–13]. For example, mice deficient in ABCB4 (ABCB42/2)
and mice with transgenic expression of Niemann-Pick C1-Like 1
in hepatocytes (L1Tg) have a ,90% decrease in biliary cholesterol
but normal fecal neutral sterol excretion presumably due to
increased TICE [7,8,13–15]. It has also been shown that TICE
can be pharmacologically stimulated with LXR agonist in
ABCB42/2 and L1Tg mice [7,13,14].
Lipoproteins must be involved in the trafficking of cholesterol to
the enterocytes for TICE. Because of its importance in hepato-
biliary cholesterol excretion [3], HDL is the lipoprotein class that
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most logically would support TICE. However, intestinal uptake of
radiolabeled cholesteryl ether from HDL is unchanged in
ABCB42/2 mice, is increased in mice deficient in the HDL
receptor scavenger receptor B-I (SR-BI), and is decreased in mice
treated with LXR agonist [14]. In addition, TICE as measured by
intestinal perfusion is increased in SR-BI deficient mice and
unchanged in ATP binding cassette transporter A1 (ABCA1)
deficient mice and mice deficient in both ABCA1 and SR-BI,
which have extremely low levels of circulating HDL [12,16]. Most
recently, it was demonstrated that TICE does not depend on
HDL-dependent delivery of plasma cholesterol to the intestine
[16].
Based upon the evidence that HDL is not directly involved in
TICE [7,14,17], we hypothesized that liver-derived, apolipopro-
tein B (apoB)-containing lipoproteins are delivering cholesterol to
the small intestine for TICE. In the current study, we tested this
hypothesis by selectively reducing the hepatic expression of
microsomal triglyceride transfer protein (MTP), which is required
for the assembly and secretion of apoB-containing very low density
lipoproteins (VLDL) [18]. We found that inhibition of hepatic
VLDL secretion reduced fecal neutral sterol excretion by .50% in
L1Tg mice, a mouse model where TICE predominates. These
studies suggest that an apoB-containing lipoprotein is responsible
for moving cholesterol from the liver to the small intestine for
TICE. We believe that our current findings will facilitate the
discovery of other components of the TICE pathway and will open
new avenues for the development of therapies that increase




Male transgenic mice expressing human NPC1L1 in hepato-
cytes (L1Tg) [15] and wild type littermate controls on a C57BL/
6N background were maintained on standard rodent chow. At 6
weeks of age, the mice were switched to a semisynthetic low-fat,
high-cholesterol diet (10% of energy as palm-enriched fat, 0.2%
cholesterol w/w) and were IP injected biweekly with 25 mg/kg of
either non-targeting antisense oligonucleotide (Control ASO-ISIS
353512 (59-TCCCATTTCAGGAGACCTGG-39) [19] or ASO
directed against murine MTP (MTP ASO-ISIS 144477 (59-
CCCAGCACCTGGTTTGCCGT-39) as previously described
[20]. After 6 weeks of treatment, mice were fasted for 4 hrs and
anesthetized with ketamine/xylazine (120/20 mg/kg IM). Bile
was collected from the gallbladder, and blood was collected by
heart puncture for plasma isolation. Following a whole body flush
with saline, liver and small intestine were collected and snap frozen
in liquid nitrogen. All mice were maintained in an American
Association for Accreditation of Laboratory Animal Care-
approved animal facility under protocols approved by the
institutional animal care and use committee at Wake Forest
University School of Medicine.
Immunoblotting of Tissue Proteins and Lipoprotein
Apolipoproteins
Pieces of liver and proximal small intestine (,100 mg) were
homogenized on ice in 25 mM Tris HCL pH 7.4, 300 mM NaCl
and 1% Triton X-100 in the presence of protease inhibitor cocktail
(Sigma). The tissue homogenate was centrifuged twice at 10,000 x
g for 10 min and protein concentration of the supernatant was
measured by Lowry assay [21]. Plasma pooled from 4–5 animals
per group was separated by FPLC [22] and fractions correspond-
ing to VLDL, LDL, transitional lipoprotein, and HDL were
collected. After mixing with 5X SDS sample buffer, the tissue
supernatant (10 mg protein/lane) and lipoprotein fractions were
separated on Novex NuPAGE 4–12% Bis-Tris Midi Gels
(Invitrogen). The proteins were transferred to nitrocellulose
membranes, which were subsequently blocked with 5% (w/v)
non-fat dried milk dissolved in wash buffer. The membranes were
incubated with one or more of the following antibodies: mouse
monoclonal to mouse MTP (BD Transduction Laboratories),
rabbit monoclonal to LDL receptor (Abcam), rabbit polyclonal to
ABCA1 (provided by Dr. John Parks, Wake Forest University
School of Medicine), mouse monoclonal to b-actin (Sigma), goat
polyclonal to human apoB (Academy Biomedical), rabbit poly-
clonal to rat apoE (provided by Dr. Joachim Herz, UT
Southwestern Medical Center). After washing, the blots were
probed with secondary antibodies against rabbit, goat, or mouse
IgG conjugated to horseradish peroxidase (Sigma). Detected
proteins were visualized with ECL reagent (PerkinElmer) and
exposure to Blue X-Ray Film (Phenix).
Quantitative Real-Time PCR (qPCR)
RNA extraction and qPCR was conducted as previously
described on individual tissue samples (n = 5 per group) [23].
Cyclophilin was used as an internal control and mRNA expression
levels were calculated based on the DD-CT method. Messenger
RNA levels for each gene represent the amount relative to that of
WT mice treated with control ASO, which was arbitrarily
standardized to 1. Primer sequences used for qPCR are available
on request.
Plasma Concentration and Distribution of Cholesterol
Plasma total cholesterol concentration and lipoprotein choles-
terol distributions were determined as described [22].
In Vivo Determination of VLDL Lipid and ApoB Secretion
Rates
After six weeks of high-cholesterol diet feeding and ASO
treatment, mice (n = 5 per treatment group) were fasted for 4 hrs,
anesthetized with isoflurane (4% induction & 2-3% maintenance,
inhalation), and injected retro-orbitally with 1) [35S]Met/Cys
(7 mCi/g body weight) to radiolabel newly synthesize apoB and 2)
tyloxapol (500 mg/kg; Sigma) to block lipolysis [24]. At 0, 0.5, 1,
2, and 3 hrs after injection, 50 ml of blood was collected from
anesthetized mice by retro-orbital bleeding. Plasma was harvested
from the blood samples and used to quantify TG and total
cholesterol (TC) mass by enzymatic assay. TG and TC secretion
rates were derived from the slope of the line of best fit of time versus
plasma TG and TC for each individual animal using GraphPad
Prism 5. Hepatic secretion of newly synthesized apoB was
measured in plasma from the 3 hr time point as described
previously [25].
Liver and Gallbladder Lipid Measurements
Lipid concentrations in liver and gallbladder bile were
determined as described previously [15].
Analysis of fecal neutral sterol excretion
After 6 weeks of treatment, fecal neutral sterol excretion was
measured as described previously [23].
Statistical Analysis
Data are expressed as the mean 6 standard error of the mean
(SEM), and were analyzed using multivariate analysis of variance
(ANOVA) followed by Student’s t tests for post hoc analysis.
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Differences were considered significant at p,0.05. All analyses
were performed using JMP version 5.0.12 (SAS Institute; Cary,
NC) software unless otherwise specified.
Results
MTP ASO treatment reduces hepatic MTP expression and
function
Male L1Tg and WT littermate controls mice were fed a low-fat,
high-cholesterol diet and treated with either a non-targeting
antisense oligonucleotide (control ASO) or an ASO targeting MTP
(MTP ASO). Because ASOs are cleared more efficiently by the
liver compared to the small intestine [26], we anticipated that
knockdown of MTP expression would be significantly greater in
liver versus small intestine, which requires MTP for assembly and
secretion of chylomicrons [18]. After six weeks of treatment,
hepatic MTP mRNA expression was reduced by ,90% in both
WT and L1Tg mice treated with MTP ASO compared to control
ASO (Figure 1A). Hepatic MTP protein expression was reduced
.75% with MTP ASO in both genotypes (Figure 1B). As
expected, intestinal MTP mRNA (Figure 1C) and protein
(Figure 1D) were minimally affected with MTP ASO treatment.
Since MTP is required for efficient efflux of hepatic lipids on
apoB-containing lipoproteins, liver lipid accumulation was dra-
matically increased in mice treated with MTP ASO. Compared to
WT mice treated with control ASO, WT and L1Tg mice treated
with MTP ASO had a 330% and 420% increase, respectively, in
hepatic cholesteryl ester (CE) (Figure 2A). MTP ASO treatment
significantly increased hepatic free cholesterol (FC) content by
31% in L1Tg but not WT mice (Figure 2B). Liver triglyceride
(TG) concentration was raised by 460% and 820% in WT and
L1Tg mice respectively with hepatic MTP knockdown (MTPHKD)
(Figure 2C). Hepatic phospholipid (PL) content was similar
amongst treatment groups (Figure 2D).
Hepatic MTP knockdown reduces fecal cholesterol
excretion in L1Tg mice
Due to the increased cholesterol accumulation in liver
(Figure 2A-B), MTPHKD was expected to cause a compensatory
elevation in biliary cholesterol concentration. Consistent with our
previous work [13,15], biliary cholesterol was reduced by 68% in
L1Tg versus WT mice treated with control ASO. However, MTP
ASO treatment did not increase biliary cholesterol in either WT or
L1Tg mice (Figure 3A). The liver can also convert excess
Figure 1. Hepatic and intestinal MTP expression following MTP ASO treatment. Liver and small intestine were collected from L1Tg and WT
mice following 6 weeks of treatment with control ASO or MTP ASO. Quantitation of MTP mRNA in liver (A) and proximal small intestine (C) was
conducted by real-time PCR using individual RNA samples (n = 5 per treatment group). Western blot analysis of MTP and b-actin in liver (B) and
proximal small intestine (D). Data in graphs represent the means 6 SEM, and means not sharing a common superscript differ significantly (p,0.05).
doi:10.1371/journal.pone.0084418.g001
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cholesterol to bile acids, but MTPHKD had no effect on bile acid
concentration in gallbladder bile (Figure 3B). The level of biliary
phospholipids was also similar amongst the treatment groups
(Figure 3C).
Despite the dramatic reduction in biliary cholesterol concen-
tration (Figure 3A), control ASO-treated L1Tg mice compared to
WT mice had normal fecal cholesterol excretion (Figure 3D),
which has been attributed to increased TICE in L1Tg mice [13].
Fecal cholesterol excretion was unchanged in WT mice with
MTPHKD (Figure 3D). However, L1Tg mice treated with MTP
ASO versus control ASO displayed a significant 53% reduction in
fecal cholesterol loss (Figure 3D). These data indicate that
inhibition of MTP-dependent hepatic lipid secretion on apoB-
containing lipoproteins reduces TICE in L1Tg mice.
Hepatic MTP knockdown decreases but does not
eliminate hepatic secretion of apoB-containing
lipoproteins
Since MTP ASO treatment reduced but did not abolish
cholesterol excretion in L1Tg mice, the hepatic secretion of lipid
and apoB was assessed in mice injected with tyloxapol and
[35S]Met/Cys [24]. MTPHKD in WT and L1Tg mice caused the
hepatic secretion rate of TG (Figure 4A,B) to be decreased by
$60% and total cholesterol (TC) (Figure 4C,D) to be reduced by
.50%. MTP ASO versus control ASO treatment caused hepatic
secretion of newly synthesized apoB100 to be significantly reduced
in L1Tg mice and to trend towards a decrease in WT mice
(Figure 4E). In contrast, hepatic apoB48 secretion was unchanged
with MTPHKD in WT and L1Tg mice (Figure 4E).
Hepatic MTP knockdown reduces plasma VLDL but not
LDL
To further evaluate the impact of hepatic MTP knockdown on
apoB-containing lipoprotein levels, plasma lipoprotein cholesterol
and apolipoprotein distribution was measured. Consistent with our
previous study [15], plasma TC (Figure 5A) and HDL cholesterol
(HDLc) (Figure 5E) were significantly increased in L1Tg versus
WT mice treated with control ASO. In addition, control ASO-
treated L1Tg mice had significantly more cholesterol associated
with transition lipoproteins (TL) (Figure 5D), which were
previously characterized as large, apoE-rich HDL [15]. As
expected, MTPHKD tended to reduce and significantly reduced
VLDL cholesterol (VLDLc) in WT and L1Tg mice, respectively
(Figure 5B). However, with MTP ASO treatment, LDL cholesterol
was significantly increased in WT mice and was unchanged in
L1Tg mice (Figure 5C), and TL cholesterol was significantly
elevated in both genotypes (Figure 5D). MTPHKD caused a
significant reduction in HDLc in L1Tg mice but no change in
HDLc in WT mice (Figure 5E). Consistent with the reduction in
VLDLc, apoB100, apoB48 and apoE were reduced in VLDL from
WT and L1Tg mice treated with MTP ASO (Figure 5H). In
contrast, MTPHKD did not affect apoB100, apoB48, and apoE
levels in LDL (Figure 5I), and increased apoB48 in TL (Figure 5J).
Hepatic MTP knockdown decreases LDL receptor in liver
In spite of the significant reduction in hepatic lipid secretion on
apoB-containing lipoproteins (Figure 4), the plasma concentration
of cholesterol and apoB associated with LDL was either increased
or unchanged in WT and L1Tg mice with MTPHKD
Figure 2. Liver lipid levels in mice with hepatic MTP knockdown. After 6 weeks of control ASO or MTP ASO treatment, fasting liver samples
were collected and analyzed for the concentrations of cholesteryl ester (A), free cholesterol (B), triglyceride (C) and phospholipid (D). All hepatic lipid
values were normalized to the protein content of the extracted tissue, and represent the means 6 SEM (9–10 mice per treatment group). Means not
sharing a common superscript differ significantly (p,0.05).
doi:10.1371/journal.pone.0084418.g002
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(Figure 5C,5I). This finding was partially explained by the
continued secretion of apoB in the face of MTPHKD (Figure 4E).
In addition, because of the significant increase in liver cholesterol
caused by MTP ASO treatment (Figure 2A,B), it was hypothesized
that hepatic LDL receptor (LDLR) was downregulated conse-
quently resulting in reduced LDL clearance. Immunoblot analysis
of liver verified that LDLR was reduced in both WT and L1Tg
mice with MTPHKD (Figure 6A). Since HDLc was significantly
reduced in MTP ASO-treated L1Tg, hepatic ATP-binding
cassette transporter (ABCA1) expression was also measured.
However, there was no significant difference in liver ABCA1
protein amongst the different treatment groups (Figure 6B).
Discussion
We hypothesized that hepatic apoB-containing lipoproteins
were involved in delivering cholesterol to the small intestine for
TICE. We tested this hypothesis by reducing hepatic MTP
expression in WT mice and L1Tg mice, which primarily excrete
cholesterol via TICE. MTP ASO treatment reduced hepatic MTP
protein expression by .75% (Figure 1), increased hepatic neutral
lipid content by .300% (Figure 2), and decreased VLDL TC and
TG secretion by .50% (Figure 4). Although biliary cholesterol
concentration was not altered, fecal cholesterol excretion was
reduced by ,50% in L1Tg treated with MTP ASO (Figure 3).
From these results, we conclude that MTP-dependent lipidation of
hepatic apoB-containing lipoproteins is necessary for proper
maintenance of TICE. Moreover, our data are the first to indicate
that VLDL or a catabolic product such as LDL is responsible for
delivering cholesterol thorough the plasma to the small intestine
for TICE.
When treated with MTP ASO, WT and L1Tg mice displayed
similar reductions in secretion of cholesterol and TG on apoB-
containing lipoproteins (Figure 4). However, MTPHKD decreased
fecal cholesterol excretion in L1Tg but not WT mice (Figure 3).
The inability of MTP ASO treatment to reduce fecal cholesterol
excretion in WT mice could be due to the hepatobiliary pathway
being intact. Under normal conditions in mice, ,70% of
cholesterol excreted in feces is derived from the bile [6–8]. Thus,
in WT mice with MTPHKD, liver cholesterol normally destined for
TICE could have been rerouted into the bile. Alternatively,
because apoB-containing lipoprotein secretion was not completely
abolished, TICE could have been only partially inactivated in the
WT mice with MTPHKD thus resulting in a reduction in TICE-
derived cholesterol excretion that was below our level of detection.
Our conclusion that hepatic apoB-containing lipoproteins
support the TICE pathway is consistent with the recent results
reported by Le May et al [27]. Using intestinal explants from
LDLR deficient mice, it was found that LDL-derived TICE was
decreased by 58%. In contrast, PCSK9 deficient mice, which
displayed ,300% increase in intestinal LDLR, had a ,60%
increase in LDL-derived TICE. These data indicate that the
LDLR feeds cholesterol into TICE by internalizing apoB-
containing lipoproteins at the basolateral surface of enterocytes
and are in concordance with our observation of an ,50%
decrease in TICE when hepatic VLDL secretion was disrupted.
Figure 3. Biliary lipid levels and fecal cholesterol excretion in mice with hepatic MTP knockdown. After 6 weeks of control ASO or MTP
ASO treatment, gallbladder bile was collected and analyzed for the concentration of cholesterol (A), bile acids (B), and phospholipids (C). For 3 days
prior to euthanasia, feces were quantitatively collected for analysis of fecal cholesterol excretion (D). Data represent the means 6 SEM (n = 7–10 per
treatment group), and means not sharing a common superscript differ significantly (p,0.05).
doi:10.1371/journal.pone.0084418.g003
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We believe that TICE was decreased in L1Tg mice with hepatic
MTP knockdown due to reduced secretion of cholesterol on apoB-
containing lipoproteins. However, MTPHKD in L1Tg mice also
resulted in a significant drop in plasma HDL cholesterol
(Figure 5E) thus raising the possibility that the reduction in
HDL was responsible for the diminution in TICE. Although HDL
is believed to play a major role in hepatobiliary reverse cholesterol
transport, data from our lab and those of others indicates that
Figure 4. Hepatic secretion of lipid and apoB with MTP knockdown. Following 6 weeks of treatment with control ASO or MTP ASO, L1Tg and
WT mice were fasted for 4 hrs and then injected retro-orbitally with tyloxapol (500 mg/kg) and [35S]Met/Cys. Blood samples were periodically
collected and the plasma was analyzed for TG (A) and TC (C) concentration. The hepatic secretion rates of TG (B) and TC (D) were determined by linear
regression analysis. Secretion of newly synthesized apoB100 and apoB48 (E) was measured by autoradiography of radiolabeled apoB that had been
immunoprecipitated from plasma collected 3 hrs post-tyloxapol injection. The autoradiography data in panel E show samples that were separated on
one gel and were exposed for the same time to the same piece of X ray film. Data represent the means 6 SEM (n = 5 per treatment group), and
means not sharing a common superscript differ significantly (p,0.05).
doi:10.1371/journal.pone.0084418.g004
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HDL does not directly participate in TICE. Intestinal uptake of
HDL CE was similar in WT and ABCB42/2 mice, which
predominantly excrete cholesterol via the TICE pathway [14]. In
addition, LXR agonist treatment, which raises TICE ,2-fold [6],
reduced HDL [3H]-cholesteryl ether accumulation in the intestine
of both WT and ABCB42/2 mice [14]. Because of an inability to
form nascent HDL, ABCA1 deficient mice (ABCA12/2) have
very low levels of plasma HDL. Nevertheless, Plosch and
Figure 5. Plasma lipoprotein cholesterol and apoliporotein distribution following MTP knockdown. After treatment for 6 weeks with
control ASO or MTP ASO, fasting plasma was collected from WT and L1Tg mice and analyzed for total cholesterol (A) and lipoprotein cholesterol
distribution, which were used to calculate the cholesterol concentration in VLDL (B), LDL (C), transition lipoprotein [TL] (D) and HDL (E). Data
represent the means 6 SEM (n = 9–10 mice per treatment group), and means not sharing a common superscript differ significantly (p,0.05). An
equal volume of pooled plasma from 4–5 mice per treatment group was separated by FPLC (F & G) and fractions containing VLDL (H), LDL (I), and TL
(J) were collected. Following SDS-PAGE, the lipoprotein fractions were immunoblotted to determine the content of apoB and apoE.
doi:10.1371/journal.pone.0084418.g005
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colleagues reported that LXR agonist treatment raised fecal
neutral sterol excretion to the same extent in ABCA1 deficient
mice and WT littermate controls [17]. Moreover, it has been
recently shown that TICE as measured by intestinal perfusion was
similar in WT and ABCA12/2 mice [16]. Scavenger receptor B-I
(SR-BI) mediates the selective uptake of cholesterol from HDL and
is expressed in the intestine [28]. Yet mice with SR-BI deficiency
(SR-BI2/2) have been shown to have either increased [12] or
unaltered TICE [16] as measured by intestinal perfusion.
Intestinal uptake of [3H]-cholesteryl ether from HDL was
surprisingly increased in SR-BI2/2 mice and was reduced when
these mice were treated with LXR agonist [14]. In addition, a
recent study by our group showed that overexpression of SR-BI in
the intestine of WT and L1Tg mice had no effect on fecal neutral
sterol excretion [29]. ApoE-rich HDL accumulate in the plasma of
L1Tg suggesting that these lipoproteins could be involved in TICE
[15]. However, our unpublished analysis of L1Tg mice lacking
apoE indicates that the absence of apoE-rich HDL has no impact
on fecal neutral sterol excretion and presumably TICE. Based
upon the published data and our findings reported in this work, we
believe that hepatic apoB-containing lipoproteins and not HDL
are primarily responsible for feeding cholesterol into the TICE
pathway.
Based upon the data presented in the current work, we propose
the following mechanism for TICE in L1Tg mice. Cholesterol
deposited into the liver by HDL or LDL is trafficked to the
basolateral membrane of hepatocytes and pumped into the bile
through the action of ATP binding cassette transporters G5 and
G8 (ABCG5/G8). NPC1L1 draws the cholesterol out of the bile
and similar to the small intestine directs the cholesterol to MTP
and acyl-CoA cholesterol acyltransferase 2 (ACAT2) that package
the cholesterol into apoB-containing lipoproteins such as VLDL.
The VLDL or a catabolic product such as LDL is trafficked to the
small intestine. Following internalization by the LDLR or another
cell surface receptor, the cholesterol is moved across the
enterocytes and is effluxed into the intestinal lumen via
ABCG5/G8. Obviously, many of the steps in our hypothetical
model of TICE need to be verified by additional studies. However,
our finding that hepatic apoB-containing lipoproteins feed
cholesterol into TICE should facilitate the discovery of the
proteins that target VLDL or LDL to enterocytes and the
intestinal receptors that internalize these lipoproteins.
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